A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind,
placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an
adjunctive treatment of Major Depressive Disorder. Study participants will continue to take
their current antidepressant therapy in addition to the study drug or placebo for the
duration of the treatment period.